C-CAR168 / AbelZeta Pharma - LARVOL DELTA

AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025 (PRNewswire) - P1 | N=30 | CAR-AID (NCT06249438) | "Overall, 10 patients have been treated with C-CAR168 including 7 LN patients, 1 Secondary Progressive Multiple Sclerosis (SPMS), 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) and 1 Immune-Mediated Necrotizing Myopathy (IMNM) patient as of February 28, 2025; Early clinical data showed that C-CAR168 was well tolerated. Four LN patients and one SPMS patient experienced low-grade 1-2 CRS with median time to onset of 2 days post C-CAR168 treatment....Four LN patients treated with C-CAR168 reached the 6-month evaluation timepoint. All 4 achieved and remained in SRI (4), 2 patients achieved CR, and 1 PR based on Kidney Disease: Improving Global Outcomes (KDIGO) 2024 LN Response Criteria."

P1 data • Lupus Nephritis • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Systemic Lupus Erythematosus

AbelZeta Announces Upcoming Oral Presentations at LUPUS 2025 (PRNewswire) - "AbelZeta Pharma, Inc...today announced the acceptance of an abstract related to C-CAR168 for presentation at the 16th International Congress on Systemic Lupus Erythematosus ('LUPUS 2025'), taking place in Toronto, Canada on May 21-24, 2025."

P1 data • Lupus Nephritis

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: AbelZeta, Inc.

New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024 (PRNewswire) - P1 | N=30 | NCT06249438 | "Potent In Vivo Cytotoxicity: In immunodeficient mouse models, a single dose of C-CAR168 demonstrated significant activity across multiple dosage levels, effectively inhibiting the growth of CD20 and BCMA single-positive or double-positive in various xenograft models....Clinical Development for C-CAR168: In an investigator-initiated trial in China targeting refractory/relapsing LN patients, 7 patients have been treated in a suboptimal dose and a potentially optimal dose. Depletion of both B cells and plasma cells in the blood in all patients were observed, accompanied by a favorable safety profile and early positive clinical signals at the suboptimal dose from patients that have had at least 3 months of follow up. Actively looking to expand into new indications such as Neuromyelitis Optica Spectrum Disorder (NMOSD), Immune-Mediated Necrotizing Myopathy (IMNM), and Systemic Sclerosis (SSc) to provide guidance for global trial to be initiated around mid 2025."

New trial • P1 data • Preclinical • Lupus Nephritis • Neuromyelitis Optica Spectrum Disorder • Systemic Sclerosis

C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases (ACR Convergence 2024) - "Based on the promising in vitro/in vivo efficacy results and safety data, C-CAR168 is being evaluated in clinical trials to treat patients with a variety of autoimmune diseases that are refractory to standard therapy."

B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL2

CAR-AID: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: RenJi Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Immunology • Inflammatory Arthritis • Lupus • Multiple Sclerosis • Myositis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases • Systemic Lupus Erythematosus • IFNG • IL10 • IL2 • IL4 • IL6 • TNFA

CAR-AID: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: RenJi Hospital

New P1 trial • CNS Disorders • Immunology • Inflammatory Arthritis • Lupus • Multiple Sclerosis • Myositis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases • Systemic Lupus Erythematosus • IFNG • IL10 • IL2 • IL4 • IL6 • TNFA